Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001558370-23-010257
Filing Date
2023-05-19
Accepted
2023-05-19 16:31:22
Documents
106
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A ibio-20221231x10qa.htm   iXBRL 10-Q/A 2268994
2 EX-31.1 ibio-20221231xex31d1.htm EX-31.1 17999
3 EX-31.2 ibio-20221231xex31d2.htm EX-31.2 17855
4 EX-32.1 ibio-20221231xex32d1.htm EX-32.1 10537
5 EX-32.2 ibio-20221231xex32d2.htm EX-32.2 6751
6 GRAPHIC ibio-20221231x10qa001.jpg GRAPHIC 67113
7 GRAPHIC ibio-20221231x10qa002.jpg GRAPHIC 71848
  Complete submission text file 0001558370-23-010257.txt   11440498

Data Files

Seq Description Document Type Size
8 EX-101.SCH ibio-20221231.xsd EX-101.SCH 104925
9 EX-101.CAL ibio-20221231_cal.xml EX-101.CAL 92400
10 EX-101.DEF ibio-20221231_def.xml EX-101.DEF 310180
11 EX-101.LAB ibio-20221231_lab.xml EX-101.LAB 641330
12 EX-101.PRE ibio-20221231_pre.xml EX-101.PRE 587181
100 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20221231x10qa_htm.xml XML 2057641
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q/A | Act: 34 | File No.: 001-35023 | Film No.: 23940745
SIC: 2834 Pharmaceutical Preparations